These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26280679)

  • 1. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors.
    Sanford RA; Song J; Gutierrez-Barrera AM; Profato J; Woodson A; Litton JK; Bedrosian I; Albarracin CT; Valero V; Arun B
    Cancer; 2015 Oct; 121(19):3422-7. PubMed ID: 26280679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications for BRCA gene mutation in breast cancer.
    Xu J; Wang B; Zhang Y; Li R; Wang Y; Zhang S
    Mol Biol Rep; 2012 Mar; 39(3):3097-102. PubMed ID: 21691706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
    Comen E; Davids M; Kirchhoff T; Hudis C; Offit K; Robson M
    Breast Cancer Res Treat; 2011 Aug; 129(1):185-90. PubMed ID: 21394499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
    Copson ER; Maishman TC; Tapper WJ; Cutress RI; Greville-Heygate S; Altman DG; Eccles B; Gerty S; Durcan LT; Jones L; Evans DG; Thompson AM; Pharoah P; Easton DF; Dunning AM; Hanby A; Lakhani S; Eeles R; Gilbert FJ; Hamed H; Hodgson S; Simmonds P; Stanton L; Eccles DM
    Lancet Oncol; 2018 Feb; 19(2):169-180. PubMed ID: 29337092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
    Atchley DP; Albarracin CT; Lopez A; Valero V; Amos CI; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
    J Clin Oncol; 2008 Sep; 26(26):4282-8. PubMed ID: 18779615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer.
    Guzmán-Arocho YD; Rosenberg SM; Garber JE; Vardeh H; Poorvu PD; Ruddy KJ; Kirkner G; Snow C; Tamimi RM; Peppercorn J; Schapira L; Borges VF; Come SE; Brachtel EF; Marotti JD; Warner E; Partridge AH; Collins LC
    Br J Cancer; 2022 Feb; 126(2):302-309. PubMed ID: 34703009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country.
    Yip CH; Taib NA; Choo WY; Rampal S; Thong MK; Teo SH
    World J Surg; 2009 Oct; 33(10):2077-81. PubMed ID: 19649760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
    Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
    Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of BRCA1 and BRCA2 Mutations Among High-risk Bahraini Patients with Breast Cancer.
    Bukamal Z; AlRayes A
    Gulf J Oncolog; 2023 May; 1(42):22-25. PubMed ID: 37283256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological characteristics of BRCA-associated breast cancers in Hispanics.
    Lagos-Jaramillo VI; Press MF; Ricker CN; Dubeau L; Mai PL; Weitzel JN
    Breast Cancer Res Treat; 2011 Nov; 130(1):281-9. PubMed ID: 21604016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
    Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV
    Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
    Zugazagoitia J; Pérez-Segura P; Manzano A; Blanco I; Vega A; Custodio A; Teulé A; Fachal L; Martínez B; González-Sarmiento R; Cruz-Hernández JJ; Chirivella I; Garcés V; Garre P; Romero A; Caldés T; Díaz-Rubio E; de la Hoya M
    Breast Cancer Res Treat; 2014 Nov; 148(2):415-21. PubMed ID: 25342642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations.
    Akkoc Mustafayev FN; Shukla MA; Lanier A; Milton DR; Gutierrez AM; Gruschkus SK; Lewis JE; Murthy RK; Arun BK
    Cancer; 2024 May; 130(9):1600-1608. PubMed ID: 38100492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
    Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
    BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA status, molecular markers, and clinical variables in early, conservatively managed breast cancer.
    Kim S; Rimm D; Carter D; Khan A; Parisot N; Franco MA; Bale A; Haffty BG
    Breast J; 2003; 9(3):167-74. PubMed ID: 12752624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
    Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Proportion of BRCA-Associated Breast Cancer Is Human Epidermal Growth Factor 2-Low and Eligible for Additional Targeted Therapy?
    Forester E; Belsare A; Kim DW; Whitaker K; Obeid E; Goldstein LJ; Bleicher RJ; Daly MB; Williams AD
    J Surg Res; 2024 Jul; 299():217-223. PubMed ID: 38776577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.